Alexandra Léary

ORCID: 0000-0002-2043-2244 · 4 papers in corpus
article 2022
2022-RA-173-ESGO Endometrioid borderline ovarian tumor: clinical characteristics, prognosis and management
·doi:10.1136/ijgc-2022-esgo.480
article 2021
Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management
Annals of surgical oncology ·doi:10.1245/s10434-021-10776-7

BackgroundClear cell borderline ovarian tumor (CCBOT) is one of the rarest subtypes of borderline ovarian malignancies. The aim of this study was to determine the prognosis of a series of CCBOT.Patients and methodsA retrospective review of …

2017
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
Oncotarget ·doi:10.18632/oncotarget.21556

Müllerian inhibiting substance, also called anti-Müllerian hormone (AMH), inhibits proliferation and induces apoptosis of AMH type II receptor-positive tumor cells, such as human ovarian cancers (OCs). On this basis, a humanized glyco-engin…

2015
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Chinese journal of cancer ·doi:10.5732/cjc.014.10289

The phosphatidylinositol 3 kinase (PI3K) pathway is frequently altered in cancer, including ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging activity in preclinical models, trials of first-generation …